drugset
drugset / Trial / NCT05960851

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

NCT05960851 ↗

Phase 1 Completed 32 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \& B). The study will last up to approximately 24 days excluding the screening period.

Timeline

Start
2023-08-09
Primary completion
2023-10-25
Completion
2023-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject OCADUSERTIB Small molecule — Oral

Indications

No indication recorded.